Bolt Biotherapeutics, Inc. (NASDAQ:BOLT – Get Free Report) VP Sarah Nemec sold 4,077 shares of the business’s stock in a transaction that occurred on Friday, September 18th. The stock was sold at an average price of $3.24, for a total value of $13,209.48. Following the transaction, the vice president directly owned 17,082 shares in the company, valued at $55,345.68. This trade represents a 19.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Sarah Nemec also recently made the following trade(s):
- On Thursday, September 17th, Sarah Nemec sold 2,922 shares of Bolt Biotherapeutics stock. The stock was sold at an average price of $3.32, for a total value of $9,701.04.
- On Wednesday, September 16th, Sarah Nemec sold 843 shares of Bolt Biotherapeutics stock. The shares were sold at an average price of $3.77, for a total transaction of $3,178.11.
Bolt Biotherapeutics Stock Up 0.8%
Shares of BOLT traded up $0.03 during mid-day trading on Monday, reaching $3.59. 22,454 shares of the stock traded hands, compared to its average volume of 27,365. The firm has a market cap of $6.93 million, a price-to-earnings ratio of -0.22 and a beta of 1.09. The stock has a fifty day simple moving average of $3.84 and a 200 day simple moving average of $4.29. Bolt Biotherapeutics, Inc. has a 12-month low of $3.10 and a 12-month high of $7.20. The company has a quick ratio of 2.61, a current ratio of 2.61 and a debt-to-equity ratio of 1.47.
Wall Street Analysts Forecast Growth
A number of equities analysts have commented on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a report on Friday, July 17th. HC Wainwright reaffirmed a “buy” rating and set a $7.00 target price on shares of Bolt Biotherapeutics in a research report on Thursday, May 28th. Finally, Rodman & Renshaw assumed coverage on Bolt Biotherapeutics in a research note on Thursday, May 28th. They issued a “buy” rating and a $22.00 price target on the stock. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Bolt Biotherapeutics presently has an average rating of “Hold” and an average target price of $14.50.
Read Our Latest Stock Report on Bolt Biotherapeutics
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in BOLT. Nan Fung Group Holdings Ltd bought a new stake in shares of Bolt Biotherapeutics in the 2nd quarter worth about $19,250. Renaissance Technologies LLC lifted its position in shares of Bolt Biotherapeutics by 40.3% during the first quarter. Renaissance Technologies LLC now owns 77,225 shares of the company’s stock worth $312,000 after purchasing an additional 22,200 shares during the last quarter. Finally, T3 Companies LLC bought a new position in shares of Bolt Biotherapeutics during the fourth quarter worth about $208,000. 86.70% of the stock is currently owned by institutional investors.
About Bolt Biotherapeutics
Bolt Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s platform is designed to stimulate the body’s innate and adaptive immune systems to recognize and attack tumor cells.
Bolt’s technology includes Boltbody™ immune-stimulating antibody conjugates, or ISACs. These therapies are intended to combine the targeting capabilities of antibodies with immune-activating components that can recruit and enhance the activity of immune cells within the tumor microenvironment.
The company’s development programs have included BDC-1001, an investigational HER2-targeted ISAC for the treatment of HER2-expressing solid tumors, and BDC-3042, an investigational antibody intended to activate macrophages through the Dectin-2 pathway.
Featured Stories
- Five stocks we like better than Bolt Biotherapeutics
- Can Bloom Energy Pop the Top Off AI’s Massive Energy Bottleneck?
- Coach’s Momentum Powers Tapestry Despite the Stock’s Sharp Pullback
- AI Is Reshaping SaaS—These 2 Software ETFs Offer Different Ways to Play It
- Insiders Signal Deep Value In DICK’s Sporting Goods
Receive News & Ratings for Bolt Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bolt Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
